Kaolin 400mg / Calcium carbonate 75mg tablets
Calcium carbonate is an inorganic salt used as an antacid.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Kaolin + Calcium carbonate
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Part of the Entrocalm brand family (generic: Kaolin + Calcium carbonate)
MHRA licensed products
View all licensed products for Kaolin + Calcium carbonate on the MHRA register
Therapeutically similar medicines
Oral liquids
(2)Other
(2)Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 4 · 1974–2026
Showing the 50 most relevant studies, sorted by most relevant.
M. Prasad, K. J. Reid, H. Murray
Applied Clay Science, 1991
Y. Leong, M. A. Bakar, Z. Ishak, et al.
Journal of Applied Polymer Science, 2004
F. Zunino, E. Boehm‐Courjault, K. Scrivener
Materials and Structures, 2020
Ahmad Syauqi Sauffi, Wan Mastura Wan Ibrahim, Mohd Mustafa Al Bakri Abdulla, et al.
IOP Conference Series: Materials Science and Engineering, 2019
Thriveni Thenepalli, Ahn Young Jun, Choon Han, et al.
Korean Journal of Chemical Engineering, 2015
A. Ababneh, Faris Matalkah, Ruba Aqel
Journal of materials research and technology, 2020
Eleraky MI, Razek TMA, Hasani IW, et al.
2025
This study evaluates the efficiency of alkali-activated Egyptian calcium bentonite, obtained from the El Alamein region in northern Egypt, for the removal of copper (Cu2⁺), lead (Pb2⁺), and nickel (Ni2⁺) from synthetic wastewater. The bentonite samples underwent a series of preparation steps, including crushing, ball milling, magnetic separation, acid treatment with 0.1N acetic acid, and alkali activation using 5% sodium carbonate (Na2CO3). Various analytical techniques, such as X-ray fluorescence (XRF), X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FTIR), cation exchange capacity (CEC) measurements, scanning electron microscopy (SEM), and free swelling analysis, were employed to characterize the materials. Absorption experiments were performed to examine the effects of pH, temperature, starting metal concentration, bentonite dose, and contact duration on heavy metal removal. The characterization results confirmed that montmorillonite was the predominant mineral in both the natural and activated bentonite samples. Adsorption studies indicated a significant improvement in heavy metal removal efficiency after activation. Under optimal conditions (pH 7, 1 g/L adsorbent dose, 120 min contact time, 20 mg/L initial metal concentration, and 20 °C), the maximum adsorption capacities of the activated bentonite were determined as 14 ± 0.03 mg/g for Cu2+, 13 ± 0.04 mg/g for Pb2+, and 12.2 ± 0.05 mg/g for Ni2+, exceeding those of the natural bentonite, which recorded capacities of 9.2 ± 0.04 mg/g, 9 ± 0.03 mg/g, and 8 ± 0.02 mg/g, respectively. Adsorption equilibrium data according to the Langmuir isotherm model, exhibiting high correlation values (R2 = 0.9979 for Cu2+, 0.9972 for Pb2+, and 0.9973 for Ni2+). Moreover, kinetic modeling demonstrated that the adsorption followed a pseudo-second-order mechanism, suggesting an intense chemisorption process. The thermodynamic analysis indicated that the adsorption process was spontaneous and endothermic, demonstrating enhanced adsorption at higher temperatures.
Abstract licence: CC BY
Luis A. Vergara, Henry A. Colorado
Construction and Building Materials, 2020
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Calcium carbonate is a basic inorganic salt that acts by neutralizing hydrochloric acid in gastric secretions.
Food interactions
1 warning
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
500 mg
Protein binding
Volume of distribution
99%
Metabolism
Elimination
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 366 interactions
When used as a nutritional supplement, calcium carbonate acts by directly increasing calcium stores within the body.
How the body processes this drug — absorption, distribution, metabolism, and elimination
ATC A02AC01
ATC A12AA04
ATC A11GB01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72